Publication:
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.

No Thumbnail Available

Date

2021-05-04

Authors

Ramos-Rincon, Jose Manuel
Perez-Belmonte, Luis M
Carrasco-Sanchez, Francisco Javier
Jansen-Chaparro, Sergio
De-Sousa-Baena, Mercedes
Bueno-Fonseca, Jose
Perez-Aguilar, Maria
Arevalo-Cañas, Coral
Bacete-Cebrian, Marta
Mendez-Bailon, Manuel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Oxford University Press
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.

Description

MeSH Terms

Aged, 80 and over
Angiotensin Receptor Antagonists
COVID-19
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Female
Hospital Mortality
Hospitalization
Humans
Hypoglycemic Agents
Male
SARS-CoV-2

DeCS Terms

Mortalidad Hospitalaria
Hipoglucemiantes
Aspirina
Inhibidores de la Enzima Convertidora de Angiotensina
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Antagonistas de Receptores de Angiotensina

CIE Terms

Keywords

Age ≥ 80, Cardiometabolic therapy, Coronavirus disease-2019, Mortality, Type 2 diabetes, Área Sanitaria Norte de Córdoba

Citation

Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109